Trials / Completed
CompletedNCT07528911
Elements of Adaptive Immunity in Epithelial Ovarian Cancer
Prognostic Significance of Adaptive Immunity Cell Infiltrates in the Microenvironment of High-grade Serous Ovarian Cancer.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 687 (actual)
- Sponsor
- Hellenic Cooperative Oncology Group · Academic / Other
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The study seeks to evaluate the presence and correlation with clinical outcome of several components of adaptive immunity (TILs, TLS, plasma cells and PD-L1 expression) in tumor specimens of patients with EOC treated with carboplatin/paclitaxel chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Assessment of elements of adaptive immunity in tumor biopsies | Tertiary lymphoid structures, Plasma cells, p53 and CD8+ T cells will be evaluated at tumor biopsies of patients with advanced ovarian cancer treated with chemotherapy. |
Timeline
- Start date
- 2023-04-01
- Primary completion
- 2025-04-01
- Completion
- 2025-06-22
- First posted
- 2026-04-14
- Last updated
- 2026-04-14
Locations
1 site across 1 country: Greece
Source: ClinicalTrials.gov record NCT07528911. Inclusion in this directory is not an endorsement.